Thermo Fisher Scientific Inc. $TMO Position Raised by Park National Corp OH

Key Points

• Park National Corp OH increased its Thermo Fisher Scientific stake by 1,067.7% in the third quarter, bringing its holdings to 6,329 shares valued at approximately $4.27 million. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher reported quarterly adjusted earnings of $6.03 per share and revenue of $11.99 billion, exceeding analyst estimates, while revenue grew 10.5% year over year. The company reaffirmed fiscal 2026 EPS guidance of $24.93–$25.33.
• TMO shares rose 2.1% to $668.43, near their 52-week high, as analysts maintained a generally positive outlook with a consensus “Moderate Buy” rating and a $628.78 price target. Insiders, however, sold 73,768 shares worth $44.1 million over the previous 90 days.

Park National Corp OH grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1,067.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,329 shares of the medical research company's stock after purchasing an additional 5,787 shares during the period. Park National Corp OH's holdings in Thermo Fisher Scientific were worth $4,272,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMO. Polaris Financial Partners purchased a new position in Thermo Fisher Scientific during the third quarter valued at approximately $32,000. Kilter Group LLC purchased a new stake in Thermo Fisher Scientific during the second quarter valued at $25,000. Legacy Wealth Managment LLC ID raised its position in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares during the period. Allied Private Wealth LLC bought a new stake in Thermo Fisher Scientific in the second quarter worth $26,000. Finally, MBM Wealth Consultants LLC purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In related news, EVP Michael Shafer sold 25,500 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company's stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph Holmes sold 420 shares of the company's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company's stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 in the last 90 days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 2.1%

NYSE TMO traded up $13.63 during trading on Monday, reaching $668.43. 653,629 shares of the company's stock were exchanged, compared to its average volume of 2,243,602. The stock has a market cap of $247.15 billion, a P/E ratio of 35.93, a price-to-earnings-growth ratio of 2.74 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $683.63. The company has a 50 day moving average price of $618.62 and a two-hundred day moving average price of $535.16.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the company earned $4.28 earnings per share. The company's revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research reports. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Piper Sandler began coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an "overweight" rating on the stock. Scotiabank assumed coverage on Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an "outperform" rating on the stock. Finally, Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $628.78.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.